Hematology TimesEC authorizes new use for ofatumumab in CLLDecember 14, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Hematology TimesEC grants venetoclax conditional approval for CLLDecember 9, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Hematology TimesFDA grants priority review to sBLA for pembrolizumabDecember 2, 2016Lymphoma & Plasma Cell DisordersPharmacyHodgkin Lymphoma
Hematology TimesFDA grants full approval for ponatinibNovember 30, 2016Leukemia, Myelodysplasia, TransplantationPharmacyALLCML
Hematology TimesNICE recommends taking ibrutinib off CDFNovember 30, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Hematology TimesEC grants ixazomib conditional approval to treat MMNovember 29, 2016Multiple MyelomaPharmacy
Hematology TimesTazemetostat receives fast track designation for DLBCLNovember 29, 2016Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesEC grants drug orphan designation for PNHNovember 26, 2016AnemiaThrombosisPharmacyBleeding Disorders
Hematology TimesEC approves nivolumab for relapsed/refractory cHLNovember 23, 2016Lymphoma & Plasma Cell DisordersPharmacyHodgkin Lymphoma
